Formulating exercise recommendations for patients with hypertrophic cardiomyopathy is challenging because of concern about triggering ventricular arrhythmias and because a clinical benefit has not been previously established in this population.
pathy is characterized by left ventricular hypertrophy in the absence of ventricular pressure overload. 3 Disease severity is markedly variable, with some individuals experiencing a normal life span with minimal complications and others carrying a high symptomatic burden. 4, 5 Hypertrophic cardiomyopathy is a recognized cause of sudden cardiac death in young competitive athletes, which has prompted international consensus recommendations against competitive sports participation for all individuals with hypertrophic cardiomyopathy. 6, 7 Whether recreational exercise is associated with an increased risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy is unknown. Current US and European guidelines, based solely on expert consensus, do not agree on the safety of moderate-intensity recreational exercise for patients with hypertrophic cardiomyopathy. 7, 8 Surveydatahave shown that patients with hypertrophic cardiomyopathy are less active than the general US population, and most patients with hypertrophic cardiomyopathy report purposefully reducing their activity after diagnosis. 9 Exercise has been associated with improved survival and reduced cardiovascular morbidity and mortality in the general population. [10] [11] [12] [13] Thus, it is important to establish evidence-based guidelines for exercise practices in patients with hypertrophic cardiomyopathy. Exercise has been studied in patients with heart failure with preserved and with reduced ejection fraction and is effective in improving cardiorespiratory fitness as measured by peak oxygen consumption (peak V O 2 ), which is an accurate measure of exercise capacity. [14] [15] [16] In the majority of patients with hypertrophic cardiomyopathy, peak V O 2 is significantly reduced, 17 and the peak V O 2 value correlates with New York
Heart Association class and quality of life (QOL). 18 The goal of this study was to determine whether an individually tailored, moderate-intensity aerobic program would improve exercise capacity among patients with hypertrophic cardiomyopathy, without exacerbating disease progression or increasing the occurrence of arrhythmic events.
Methods

Study Design
The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy (RESET-HCM) was a randomized clinical trial of individualized moderate-intensity aerobic exercise training vs usual activity in patients with hypertrophic cardiomyopathy performed at the University of Michigan (coordinating center) and Stanford University. The institutional review boards of both centers approved the trial design (study protocol available in Supplement 1). All participants provided written informed consent before enrollment. After randomization, exercise assignment was not blinded, although study staff who collected data on study outcomes were unaware of study group assignments and all data analyses were blinded.
Recruitment took place between April 2010 and October 2015. Patients were randomized (1:1) by a single investigator blinded to patient identity (S.M.D.) to a moderate-intensity aerobic training intervention or usual activity using the minimization technique, 19 stratified by age (18-29; 30-50; >50 years), sex, and presence of left ventricular outflow tract (LVOT) obstruction at rest (LVOT peak gradient <30 mm Hg or ≥30 mm Hg). An independent data and safety monitoring board was responsible for study oversight.
Outcomes
The primary outcome was change in peak V O 2 from baseline to week 16. Secondary outcomes included measures of change in cardiac remodeling, QOL, and exercise performance. Cardiac remodeling measures included magnitude of cardiac hypertrophy, left ventricular chamber dimensions, systolic and diastolic function, and scar volume as assessed by a combination of echocardiography and cardiac magnetic resonance imaging (CMR), plasma B-type natriuretic peptide concentration, and degree of LVOT obstruction. Quality of life measures included the Minnesota Living With Heart Failure Questionnaire (MLHF) (range, 0-105; higher scores indicate worse QOL; minimal clinically important difference, 5 points), the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR 16 ) (range, 0-27; higher scores indicate more severe depression), and the 36-Item ShortForm Health Survey Version 2 (SF-36v2) (8 subscales and 2 component summary scores; range, 1-100; lower scores indicate more disability; minimal clinically important difference, 3 to 5 points).
Exercise performance measures included other measures of exercise capacity, including exercise time, peak metabolic equivalent of tasks (METs), minute ventilation/carbon dioxide production (VE/VCO 2 ) slope, and anaerobic threshold. Nonfatal arrhythmias including occurrence of nonsustained ventricular tachycardia (NSVT), atrial arrhythmias, and change in premature ventricular contraction (PVC) burden were also assessed. Major adverse events were defined as death, aborted sudden cardiac death, appropriate implantable cardioverter-defibrillator (ICD) shock, and sustained ventricular tachycardia.
Patients included in the study were 18 to 80 years of age and had a diagnosis of hypertrophic cardiomyopathy defined by left ventricular hypertrophy with end-diastolic wall thickness 15 mm or greater on 2D echocardiography in the absence of other primary causes of left ventricular hypertrophy or wall thickness between 13 and 15 mm in the presence of other features suggestive of hypertrophic cardiomyopathy, such as systolic anterior motion of the mitral valve leaflets, family history of hypertrophic cardiomyopathy, or positive genetic test result. 5 Major exclusion criteria included a history of exerciseinduced syncope or ventricular arrhythmias; medically refractory LVOT obstruction being evaluated for septal reduction therapy; less than 3 months after septal reduction therapy or ICD placement; history of hypotensive response with exercise testing (>20 mm Hg decrease of systolic blood pressure from baseline blood pressure or an initial increase in systolic blood pressure followed by a decrease of systolic blood pressure >20 mm Hg) 20, 21 ; clinical decompensation in the previous 3 months, defined as New York Heart Association class IV congestive heart failure symptoms or Canadian Cardiovascular Society class IV angina symptoms; left ventricular ejection fraction less than 55% by echocardiography; life expectancy less than 12 months; pregnant or planned pregnancy; inability to exercise owing to noncardiovascular limitations; and unwillingness to refrain from competitive sports, burst activity, or heavy isometric exercise for the duration of the study.
Study Procedures and Timeline
Baseline studies included history and physical examination, a physical activity questionnaire assessing average weekly frequency and duration of exercise sessions in the previous month, 12-lead electrocardiography, serum biomarker analysis, genetic testing (eMethods in Supplement 2), transthoracic echocardiography, CMR, cardiopulmonary exercise testing, and QOL assessment. Participants reported their sex and race/ethnicity, with options defined by the investigators (sex: male, female; race: white/Caucasian, black/African American, Asian, American Indian/Alaskan native, Native Hawaiian/Pacific Islander, Hispanic/Latino, other). Race was assessed only to provide information about the study sample and was not considered to have an association with any of the prespecified outcomes.
Patients randomized to the exercise training group participated in a structured, unsupervised exercise program individually prescribed based on heart rate reserve derived from the baseline cardiopulmonary exercise test. Exercise was initiated at a minimum of 3 sessions per week, 20 minutes per session, at a heart rate corresponding to 60% of heart rate reserve (resting heart rate +0.6 [maximal heart rate minus resting heart rate]). A rating of perceived exertion on the Borg scale 22 was used as a secondary measure of goal exercise intensity, and participants were instructed to maintain an intensity correlating to perceived exertion ratings between 11 to 14, which correlates with a moderate level of intensity. The exercise prescription was designed to increase duration of exercise by 5 to 10 minutes every week, up to 60 minutes per session, 4 to 7 sessions per week, and then incrementally increase training intensity to a goal of 70% of heart rate reserve during the first month of the study protocol. Patients were instructed to maintain their exercise regimen from weeks 5 through 16 of the protocol. Modes of exercise included cycling, walk-jog protocols, and elliptical training. No strength training or burst-type activity was prescribed. Patients in the exercise group received a 1-hour exercise consultation with a certified exercise physiologist. Patients randomized to the usual-activity group were not provided with a formal exercise prescription at study entry and were instructed to continue their current activity practices through the duration of the study without any exercise directives. As an incentive for participation, patients in the usualactivity group were provided with an exercise consultation and exercise prescription at the conclusion of the study protocol.
All patients in both groups were provided heart rate monitors (Timex Group; Polar USA Inc) and pedometers (Omron Healthcare Inc). All patients also underwent 24 hours of continuous rhythm monitoring on enrollment, followed by automatically triggered arrhythmia detection monitoring in their first month of study participation. Adherence to the study protocol was evaluated among all participants by activity logs and weekly telephone follow-up, including the Stanford 7-day recall and downloadable data from heart rate monitors and pedometers. Physical activity data were tabulated into METs using the 2011 Compendium of Physical Activities. 23 MET-hours of activity were also calculated by multiplying METs of each activity by time spent in hours. All patients were asked to return for evaluation 4 months after enrollment and underwent the same procedures as at the baseline visit. All electrocardiograms (investigator S.S.), echocardiograms (S.S.), CMR images (P.P.A., A.A.), cardiopulmonary exercise test studies (W.H.), and QOL surveys (S.S.) were interpreted at the coordinating center, blinded to study group assignment. Additionally, V O 2 and V E/V CO 2 slope at the anaerobic threshold were assessed in a random sample of 50 cardiopulmonary exercise tests (including studies from both sites) at the coordinating center by 2 interpreters (W.H. and Jacob Sitzman, BS, RCEP, CCES, University of Michigan School of Medicine), with calculated κ statistic of 0.96 and 0.79, respectively. Eleven percent of enrollment cardiopulmonary exercise tests and echocardiograms and 5% of enrollment CMRs were obtained as part of routine clinical evaluation.
Statistical Analysis
At our centers, the mean peak V O 2 for patients with hypertrophic cardiomyopathy was 24 mL/kg/min at the time of the design of RESET-HCM. 24 Data from small studies of exercise training for patients with chronic heart failure available at the time of study design demonstrated an approximately 20% increase in peak V O 2 with 8 to 12 weeks of exercise. [25] [26] [27] Assuming a similar effect size could be expected in patients with hypertrophic cardiomyopathy, the study was powered to detect a difference of 20% (4.8 mL/kg/min) in peak V O 2 between the 2 groups with 90% power and a 2-tailed significance of .05 or less, which required 117 participants. Assuming an attrition rate of 17% (15%-20%), the planned recruitment was increased to a total of 136 patients. Statistical analyses were performed by the coordinating center using SAS software version 9.3 (SAS Institute). Statistical comparisons of the study groups with respect to clinical outcomes were performed according to the intention-totreat principle. Patient characteristics are expressed as mean (SD) or median (interquartile range) for continuous variables and frequencies and percentages for categorical variables. Change in patient characteristics over time were performed using the t test for continuous variables and χ 2 or Fisher exact test for categorical variables. The Kruskal-Wallis test was used for testing differences in medians. Data that were not normally distributed were log transformed for statistical analysis. The primary efficacy analysis was performed using analysis of variance and linear regression, with baseline peak V O 2 value as covariate. A secondary analysis of the effect of exercise training was performed using multiple linear regression with the baseline value of the outcome measure, site, and genetic status as covariates.
A post hoc sensitivity analysis of the primary outcome was performed by multiple imputation with 10 interactions on all patients randomized by using demographics, baseline characteristics, baseline comorbidities, and baseline cardiopulmonary exercise test parameters. Linear regression was performed on the change in peak V O 2 , adjusting for baseline value. In additional post hoc analyses, submaximal exercise studies, defined as those with peak respiratory exchange ratio less than 1.05, were removed from the primary end point analysis and analysis of variance was performed. To control for variability in peak effort, V O 2 attained at respiratory exchange ratio 1.0 was analyzed by group. Comparison of the PVC burden over time also was performed.
Statistical significance was set at P < .05 using 2-sided tests for the assessment of the primary outcome. Analyses of outcomes for cardiac remodeling, QOL, and secondary measures of exercise performance were not adjusted for multiple comparisons and therefore are considered exploratory and hypothesis generating.
Results
Patient Characteristics
During a 5-year period, 728 adult patients with hypertrophic cardiomyopathy were screened for trial eligibility (Figure 1) , and 136 participants (16.9% with obstructive hypertrophic cardiomyopathy; 42% women; mean age, 50.4 [SD, 13.3] years) were randomized into exercise training and usualactivity groups. Baseline characteristics of patients in each group are shown in Table 1 . All but 1 of the participants who completed the protocol underwent genetic testing. Baseline clinical characteristics did not change over time (eTable 1 and eTable 2 in Supplement 2). The attrition rates in the exercise training and usual-activity groups were comparable at 16 weeks (14.9% vs 18.8%, respectively, P = .54). Baseline clinical characteristics between participants who completed the study compared with those who withdrew from the study were also similar (eTable 3 in Supplement 2).
Primary End Point
At 16 weeks, mean change in peak V O 2 was +1.35 (95% CI, 0.50 to 2.21) mL/kg/min among participants in the exercise training group and +0.08 (95% CI, −0.62 to 0.79) mL/kg/min among participants in the usual-activity group (betweengroup difference, 1.27 [95% CI, 0.17 to 2.37] mL/kg/min) (Figure 2) , representing an absolute increase of 6% (95% CI, 1.27% to 22.7%) compared with baseline values. Adjustment for baseline genetic status and study site did not attenuate the improvement in peak V O 2 observed in the exercise training group compared with the usual-activity group (difference in increase in peak V O 2 of +1.29 mL/kg/min [95% CI, 0.20 to 2.38 mL/kg/min]; P = .02).
Exploratory End Points
Measures of Cardiac Remodeling There were no significant differences between the exercise training group vs the usual-activity group at 16 weeks in terms of changes in any measures of cardiac morphology or function (eTable 4 in Supplement 2), in LVOT gradient (eTable 4 in Supplement 2), or in serum B-type natriuretic peptide levels (eTable 2 in Supplement 2).
Quality of Life
Among the outcomes examining effects of exercise training on QOL, there were no significant differences between the exercise group and the usual-activity group at 16 weeks in terms of 9 scores of the SF-36v2 subscales, the QIDS-SR 16 score, or 3 scores on the MLHF measures. The only significant difference between groups was for the SF-36v2 physical functioning scale (increase of 5.7 points in the exercise group and decrease of 2.5 points in the usual-activity group; difference, +8.2 points [95% CI, 2.6 to 13.7 points]) (eTable 5 in Supplement 2).
Exercise Performance
Based on physical activity surveys completed at the time of study initiation, there were no significant differences between the groups in the weekly average time spent exercising. Prior to enrollment, 66 participants in the usual-activity group and 65 in the exercise training group responded to a survey of current exercise habits. Twenty-seven (41%) of the participants in the usual-activity group and 29 (45%) in the exercise training group reported no regular exercise. Of those who did report regular exercise, the majority walked (25/39 [64.1%] in the usual-activity group, 26/36 [72.2%] in the exercise training group). During the study protocol, 7 of 28 (28%) participants in the usual-activity group and 26 of 28 (93%) in the exercise training group who reported no prior history of regular exercise engaged in regular weekly exercise. During the study, participants in the exercise training group exercised a mean of 1.5 days more per week than those in the usual-activity group (3.6 days vs 2.1 days) and spent more time engaged in intentional exercise (eTable 6 in Supplement 2). The most common modes of exercise during study participation were walking, jogging/running, swimming, elliptical use, and cycling.
Post Hoc Analyses
Sensitivity Analyses of the Primary Outcome Peak V O 2 In a sensitivity analysis of the primary outcome, performed using multiple imputation and including all participants in the trial (n = 136), the mean change in peak V O 2 was +1.50 mL/kg/min (95% CI, −5.1 to 8.1 mL/kg/min) in the exercise training group and +0.17 mL/kg/min (95% CI, −5.4 to 5.7 mL/kg/min) in the usual-activity group (difference, 1.22 mL/kg/min [95% CI, 0.09 to 2.35 mL/kg/min], adjusting for baseline peak V O 2 ).
Additional Post Hoc Analyses
When CPET studies with peak respiratory exchange ratio (RER) less than 1.05 (indicating less than maximal effort [n = 13]) were removed from the analysis, the change in peak V O 2 was +1.36 mL/kg/min in the exercise training group and +0.06 mL/kg/min in the usual-activity group (between-group difference, 1. f Diastolic dysfunction severity determined according to American Society of Echocardiography criteria. g Usual activity n = 63, exercise n = 59. h Usual activity n = 41, exercise n = 36. i Usual activity n = 40, exercise n = 36. j Usual activity n = 30, exercise n = 28. k Genetic testing included the sequencing of at least 9 sarcomere genes (eMethods in Supplement 2). Patients were classified as having a pathogenic mutation if at least 1 disease-causing mutation in 1 of the 9 genes was identified. Variants were considered of uncertain significance if they could not be definitely classified as either disease-causing or benign. Patients negative for sarcomere mutations did not have any variants identified in any of the 9 sarcomere genes.
Adverse Events
There were no occurrences of major adverse events, including death, aborted sudden cardiac death, appropriate ICD shocks, or sustained ventricular tachycardia in either group. Exercise training was not associated with an increased occurrence of any nonfatal arrhythmias ( Table 2) . Three participants in the exercise group were withdrawn from the study after randomization because of symptomatic NSVT. All 3 were withdrawn based on the recommendations of the data and safety monitoring board. One patient who had a history of NSVT experienced 30 seconds of NSVT on day 1 after enrollment, prior to starting the exercise program, and was referred for ICD implantation. A second patient with a history of NSVT who already had an ICD implanted experienced more frequent episodes of symptomatic NSVT unrelated to exercise. The third patient had no history of NSVT and experienced a 28-beat run of NSVT on day 13 of the protocol, 1 hour after exercising, and was referred for ICD implantation.
Discussion
In this preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise compared with usual activity resulted in a statistically significant but small increase in exercise capacity at 16 weeks. No major adverse effects occurred, and there was no difference between the groups in rates of nonsustained ventricular arrhythmias or atrial fibrillation. Analyses of other outcomes of cardiac remodeling, QOL, and exercise performance revealed no differences between the exercise training group and usualactivity group, except for improvement of scores on QOL physical function scale, peak METs on cardiopulmonary exercise test, and PVC burden favoring the exercise group. However, these findings were not adjusted for multiple comparisons and therefore should be interpreted cautiously and should be considered exploratory and hypothesis generating.
The findings from this randomized clinical trial provide support for moderate-intensity aerobic exercise for improving exercise capacity in patients with hypertrophic cardiomyopathy. The magnitude of improvement in peak V O 2 was modest, with an absolute increase of 1.27 (95% CI, 0.17 to 2.37) mL/kg/min in the exercise training group compared with the usual-activity group, representing an absolute increase of 6% (95% CI, 1.27% to 22.7%). In the largest study of exercise in patients with heart failure (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training [HF-ACTION]), 15, 28 the exercise intervention was associated with an absolute increase in peak V O 2 of 0.6 mL/kg/min (95% CI, 0.43 to 0.77), or 4%. 15 In HF-ACTION, every 6% increase in peak V O 2 was associated with an 8% lower risk for cardiovascular mortality or heart failure hospitalizations. 29 Moderate-intensity aerobic exercise improves overall cardiovascular health and survival in the general population. [11] [12] [13] 30 Because hypertrophic cardiomyopathy is a recognized cause of sudden cardiac death in young competitive athletes, there is uncertainty about whether lower-intensity exercise could predispose these patients to a similar risk. In the absence of evidence to the contrary, many physicians caring for patients with hypertrophic cardiomyopathy recommend extremely conservative physical activity restrictions, and many patients are fearful of engaging in exercise at any level. 31 Despite the need for data to inform such recommendations, 7, 8 to our knowledge, no clinical trial has previously implemented an exercise intervention in patients with hypertrophic cardiomyopathy. 32 The current study demonstrates the feasibility of implementation of a 16-week structured exercise program for patients with hypertrophic cardiomyopathy, with no major adverse events observed in either group. The study population included a substantial percentage of higher-risk individuals, with more than 30% of patients having defibrillators and 4% having a prior history of sustained ventricular tachycardia or aborted sudden cardiac arrest. a Usual activity n = 61, exercise n = 57 (number in each group with arrhythmia detection monitoring data).
b Minor musculoskeletal injury defined as mild or moderate discomfort.
c Major musculoskeletal injury defined as persistent incapacity. Reduced peak V O 2 has been shown to correlate with clinical decompensation and mortality in hypertrophic cardiomyopathy. [33] [34] [35] No medications or interventions have yet been shown to improve peak V O 2 in patients with hypertrophic cardiomyopathy. This study provides preliminary support for a regimen of unsupervised brisk walking 4 to 7 days per week for a minimum of 30 minutes, as a targeted intervention for patients with hypertrophic cardiomyopathy. This study also provides the rationale for future studies examining longer-term outcomes related to exercise training in this population. The individualized exercise prescriptions in this study did not exceed a level considered within acceptable limits for recreational exercise for patients with hypertrophic cardiomyopathy. 8 Yet participants in the exercise training intervention exercised more frequently and purposefully than those in the usual-activity group, suggesting that an exercise consultation to establish an individualized exercise training program for patients with hypertrophic cardiomyopathy may be considered in clinical practice to promote a healthy, active lifestyle.
Moderate Exercise and Oxygen Consumption in Hypertrophic Cardiomyopathy
Limitations
This study has several limitations. First, there is a potential for sampling bias, because 386 of 728 potential study participants declined to participate and another 206 were excluded. However, the clinical characteristics of the patients enrolled in this study were similar to characteristics in the entire cohorts at our respective institutions, as well as those in published series from other institutions. 33, 36 Second, the effect size of exercise training in patients with hypertrophic cardiomyopathy was relatively modest and was substantially less than the anticipated effect size on which the study was powered (ie, 20% relative improvement, absolute improvement of 4.8 mL/kg/min in peak V O 2 in the exercise training group compared with the usual-activity group). The anticipated effect size was based on small studies of exercise training in patients with heart failure who were available at the time of study design. [25] [26] [27] Since then, the largest exercise training study in patients with heart failure, HF-ACTION, demonstrated a much more modest relative improvement in peak V O 2 (median, 4% increase). 15 Third, although there were no major adverse events and no signal for harm in any of the participants, the study was not powered to assess safety of the exercise intervention. Such a study would require a substantial sample size, given the relative rarity and infrequency of major adverse events in patients with hypertrophic cardiomyopathy compared with those with chronic heart failure. 4 While there was no evidence that exercise-induced hypertrophic or fibrotic remodeling, future studies with longer follow-up will be required to assess any potential influence of exercise on disease progression. Fourth, because of the nature of the intervention, it was not possible to blind patients to treatment assignment. In the absence of blinding, self-reported QOL scores may be biased by patient expectations.
Fifth, the exercise prescription used in this study only incorporated moderate-intensity aerobic exercise in adult patients. Future studies will need to address the safety and benefits of more vigorous aerobic exercise and isometric activities, including participation in competitive sports, in both adult and pediatric patients with hypertrophic cardiomyopathy.
Conclusions
In this preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise compared with usual activity resulted in a statistically significant but small increase in exercise capacity at 16 weeks. Further research is needed to understand the clinical importance of this finding in patients with hypertrophic cardiomyopathy, as well as the long-term safety of exercise at moderate and higher levels of intensity. 
ARTICLE INFORMATION
Abstract
The overall goal of this project is establish the safety profile and potential benefits of exercise training in patients with hypertrophic cardiomyopathy (HCM). HCM is the most common genetic cardiovascular disease with a broad spectrum of disease severity. HCM accounts for >30% of cases of sudden cardiac death in young athletes. This has appropriately led to the establishment of national guidelines for participation in recreational exercise, with the consensus of expert opinion being that moderate aerobic activities are generally allowable. However, data on safety of recreational fitness, useful parameters for risk stratification, and methods of devising individual exercise prescriptions are completely lacking. There is compelling animal data that voluntary exercise is not only safe, but can prevent or even reverse many of the pathologic features of HCM. There is an urgent need is to address the paradox of exercise in HCM; that is, striking a reasonable balance between potential acute risk of sudden death and the many well-established long term health and cardiovascular benefits of a regular exercise program. Large clinical trials of exercise training in patients with atherosclerosis and heart failure with equivalent acute risks, have shown safety, improved functional capacity, lower mortality, and reduced hospitalizations. We propose a pilot randomized controlled trial to determine the safety and efficacy of moderate intensity exercise in HCM patients. Aim 1 is designed to determine the safety of moderate intensity exercise in patients with HCM. The focus of this aim will be on devising individualized training protocols based on parameters derived from baseline cardiopulmonary exercise testing. A secondary goal will be to assess for exercise induced arrhythmias. Aim 2 examines whether exercise training improves functional capacity, clinical phenotypic characteristics, and quality of life in patients with HCM. Pilot data will greatly enhance the competitiveness of this proposal for extramural funding.
Specific Aims
The goal of this randomized clinical pilot trial is to establish the safety profile and potential benefits of moderate intensity exercise in patients with HCM. Participation in competitive athletics is associated with an increased risk of sudden cardiac death (SCD) in individuals with structural heart disease, most commonly HCM. This has appropriately led to the establishment of national guidelines based on expert opinion that discourage participation in high intensity competitive sports, burst exertion (e.g., sprinting), or isometric exercise (e.g., heavy lifting). Non-competitive, low to moderate intensity exercise is allowable, although many physicians and HCM patients are still understandably apprehensive. Data on the safety of a recreational exercise program, and how to gauge appropriate intensity level, are desperately needed so that HCM patients can reap the well established health benefits of regular physical activity. Limited, but compelling animal data suggest that moderate intensity exercise is not only safe, but may also prevent or even reverse cardiac hypertrophy, fibrosis, myocellular disarray, and apoptosis associated with HCM. There are no published studies on exercise in patients with HCM, although large clinical trials in heart failure have shown exercise training to be safe, to improve functional capacity and quality of life, and to lower cardiovascular mortality. The pilot randomized control trial proposed here is the first to determine the safety of moderate intensity exercise training and explore its potential benefits in patients with HCM. Pilot data will greatly enhance the likelihood of extramural funding for a larger randomized clinical trial intended to establish the long-term effects of exercise on HCM pathophysiology.
Specific Aims:
Aim 1: To determine the safety of a moderate intensity exercise training program in patients with HCM. A. Randomize patients to home exercise training or usual activity.
B. Devise an individualized exercise training protocol using a percentage of heart rate reserve and rating of perceived exertion as the targets for exercise intensity. C. Monitor for exercise induced arrhythmias using a 30 day ambulatory electrocardiographic monitor, and for other symptoms (i.e., dizziness, chest pain, syncope) recorded in a daily log.
Hypothesis: Exercise parameters derived from a baseline cardiopulmonary exercise test will target an appropriately safe level of exercise intensity that will not cause significant arrhythmias or exacerbate symptoms.
Aim 2:
To determine whether exercise training improves functional capacity, clinical phenotypic characteristics, and quality of life in patients with HCM. A. Compare peak oxygen consumption by cardiopulmonary exercise testing before and after 4 months of exercise training. B. Quantitatively determine effects of exercise on hypertrophy, left ventricular obstruction, left ventricular mass and fibrosis using echocardiography and cardiac magnetic resonance imaging. C. Administer quality of life questionnaires before and after exercise intervention.
Hypothesis: Exercise training in HCM patients for 4 months will result in significant improvements in peak oxygen consumption and quality of life, with neutral effects on the clinical phenotype.
Background and Significance
HCM is the most common genetic cardiovascular disease, affecting approximately 1:500 individuals. It is characterized by a hypertrophied, non-dilated left ventricle in the absence of another cardiac or systemic disease capable of producing the degree of hypertrophy present. HCM is a progressive disease with highly variable phenotypic expression with regard to age of onset, magnitude of hypertrophy, presence/degree of left ventricular outflow obstruction, presence and severity of symptoms and inherent risk of sudden cardiac death. Large-scale controlled and randomized study designs, such as those that have provided important answers regarding the management of coronary artery disease and congestive heart failure (CHF), have generally not been available in HCM. Thus, the level of evidence governing management decisions has often been derived from non-randomized and retrospective studies. Importantly, there are no therapeutic strategies or lifestyle modifications that have been shown to impact the progression of disease. This provides the rationale for the current proposal with the long-term goal of exploring the possibility that habitual exercise can improve outcomes in HCM patients.
Well established health benefits of exercise
While the link between physical activity and health benefits has been intuitively known for decades, physical inactivity still remains a major health problem. A staggering 200,000 deaths annually in the United States are attributable to a sedentary lifestyle. 2 Conversely, observational studies show that regular exercise confers a significant survival benefit. 3, 4 Habitual exercise significantly decreases the risk of coronary heart disease (CHD), cardiac events and cardiovascular death, [5] [6] [7] [8] and improves outcomes in patients with established CHD. [9] [10] [11] [12] The benefits of regular exercise on CHD risk may be mediated, in part, by the favorable influence on plasma lipoproteins, systemic blood pressure, obesity, diabetes mellitus, and psychosocial well-being. Endurance exercise training significantly lowers total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and raises high-density lipoprotein cholesterol independent of diet, baseline body fat, or change in body fat. 13 Long-term aerobic exercise also lowers systemic blood pressure, 14, 15 reduces body fat and preserves body lean mass compared to a weight loss diet alone, 16 and prevents diabetes. [17] [18] [19] [20] Additionally, regular exercise has been shown to reduce stress, anxiety and depression, 21 which are major CHD risk factors.
In patients with chronic HF, both chronic hypoperfusion and physical inactivity lead to skeletal muscle dysfunction and exercise intolerance. Numerous studies have demonstrated the safety and efficacy of exercise training in patients with HF. [22] [23] [24] [25] [26] [27] [28] [29] [30] Randomized controlled trials have shown that exercise training can lessen symptoms, increase exercise capacity, improve quality of life, 31, 32 reduce hospitalization and increase survival 36, 37 over and above traditional medical therapy such as ACE inhibitors and beta blockers. Exercise also lowers lifetime risk of developing heart failure. 33 
Given these convincing data, it is imperative to understand how HCM patients can safely attain the well established, lifelong health benefits of regular exercise.
Basic studies relevant to effects of exercise on HCM pathology
There are compelling animal data that support the concept that moderate voluntary exercise is not only safe, but can prevent or even reverse many of the pathologic features of HCM. Transgenic mice expressing a mutant myosin heavy chain that develop pathology by 6 to 8 months of age were exposed to voluntary cage wheel running. 34 As in human HCM, these mice display an increase in heart to body weight ratio and histopathologic changes such as myofibrillar disarray and fibrosis. Transgenic mice exhibited similar exercise performance and physiologic cardiac adaptation to exercise as non-transgenic mice (NTG). There was no difference in mortality between HCM and NTG exercised mice, proving the safety of moderate intensity exercise in HCM mice. Voluntary exercise led to lessened hypertrophic gene induction, myocyte disarray, and apoptotic signaling regardless of whether exercise was initiated before or after HCM pathology was established. Interestingly, a reduction in fibrosis was only observed when exercise was initiated in the pre-pathologic mice. Another study of a transgenic mouse model of dilated cardiomyopathy (DCM) showed that chronic swim training significantly improved survival and cardiac function, suppressed expression of cardiac hypertrophic markers, and enhanced signaling pathways involved in effective metabolic energy handling. 35 These data suggest a role for exercise as a therapeutic strategy that can prevent or delay the onset of pathology in this disease process.
The potential role of exercise as a therapeutic strategy to prevent or delay the onset of pathology in
HCM has yet to be explored in human studies.
Relevance of sudden death risk associated with competitive exercise to the proposed studies
Participation in competitive athletics confers an increased risk of SCD. In one Italian study, the relative risk of cardiovascular SCD in athletes (12-35 years of age) was 2.45 compared to nonathletes. 36 The acute, physiological, emotional, and psychological effects of exercise, along with often extreme or unpredictable environmental conditions are thought to be the primary triggers of life threatening arrhythmias in individuals with underlying cardiovascular conditions. This is supported by the fact that SCD in athletes most often occurs during or shortly after intense training or competition. 37, 38 Although the overall annual rate of SCD in US athletes is fortunately relatively low at 1 in 50-200,000, 38 the impact of each and every young athlete's death is immeasurable.
HCM accounts for >30% of cases of SCD among athletes. 37 The incidence of HCM-related SCD is much higher in high-intensity sports, such as basketball and football. 37, 39, 40 Nevertheless, significant concern about the safety of any form of exercise has prompted establishment of national guidelines discouraging participation in virtually all competitive sports. Although no data on safety of recreational exercise exist, a consensus of expert opinion is that many recreational activities of low-moderate aerobic intensity (i.e. walking, bicycling, light jogging, swimming) are generally safe 41 .
While SCD risk with vigorous exercise in HCM patients is not to be minimized, in considering the risks of an exercise intervention in HCM patients it is also important to bear in mind the following three points. First, that habitual exercise substantially lowers the relative risk of sudden death in the general population. 42, 43 Second, several large clinical studies over the past decade in patients with chronic stable heart failure demonstrate the safety and many benefits of habitual exercise. 25, [44] [45] [46] Finally, ventricular arrhythmias during symptom-limited exercise are extremely rare in patients with HCM. 47 
Value of cardiopulmonary stress testing
Cardiopulmonary exercise testing with metabolic monitoring is an essential component of the objective assessment of functional ability in chronic heart failure. Its value in HCM is less well studied. There are no published reports on the role of cardiopulmonary exercise testing as a means of risk stratification or for guiding exercise recommendations in patients with HCM, as shown in the heart failure population. 31, 46 The key measurement is peak oxygen uptake (peak VO 2 ), whose usefulness as a prognostic marker in heart failure is widely accepted. 48 Peak VO2 and anaerobic threshold have been shown to be compromised in patients with HCM, 49 but prognostic implications are not as well understood. For heart failure patients, well-tolerated exercise programs associated with such favorable training responses have targeted exercise intensity ranges below anaerobic threshold, at 50-70% of maximum oxygen consumption which corresponds to 60-80% of maximum heart rate reserve, and/or a rating of perceived exertion of 12-14 on the Borg scale. 50 
Use of cardiopulmonary testing parameters to provide exercise prescriptions for HCM patients has not been studied.
In summary, there are convincing data that exercise training in heart failure patients improves outcomes, and compelling studies in animal models of HCM show benefits of exercise training in prevention and even regression of many pathologic features. Furthermore, patients with HCM are in no way immune to developing other forms of cardiovascular disease, and thus stand to reap equal benefit from a regular exercise program well documented to reduce risks for acquiring coronary heart disease risk factors, myocardial infarction, stroke, heart failure and premature death in the general population. However, there are no data on safety and potential benefits of recreational fitness, useful parameters for risk stratification, or methods of devising individual exercise prescriptions in individuals with HCM. The pilot randomized study proposed here will begin to address these important questions.
Previous Related Work
We perform cardiopulmonary exercise echocardiography on virtually all HCM patients and collect this data in our Velos registry, created and managed by MICHR. In preparation for initiating an exercise training study, we designed a voluntary survey drawing questions from the 2005-2006 National Health and Nutrition Examination Survey (NHANES) to ascertain exercise practices and administered it to a national HCM population (HCMA). In a preliminary analysis, data from HCM patients (n=835) were compared to published data from eligible NHANES participants (n=9,465) using Chi 2 analysis or student t-tests to compare demographics and exercise practices. Compared to NHANES respondents, fewer HCM patients participate in vigorous recreational activity (23% vs 45% respectively, P <0.001), although more HCM patients exercised moderately (62% vs 59%, HCM vs NHANES respectively, P <0.05). Mean age (46 vs 31 y, P<0.001), gender (53 vs 49% male, P=0.02), race (90 vs 69% Caucasian, P<0.001) and body mass index (29 vs 27, P<0.001) were significantly different in HCM vs eligible NHANES populations, respectively. Demographic differences limit comparisons to the general population and future analysis will use propensity matching to account for these differences between groups. Nevertheless, we can conclude that few HCM patients perform vigorous exercise and ~1/3 are not engaging in moderate exercise recommended for overall health benefit. In addition, sixty one percent of respondents indicated that exercise restrictions impact their emotional well being. This highlights the need for further investigation into the many potential benefits of exercise in the HCM population.
Research Design and Methods
Overall study design We propose to study 128 patients (see power calculation below) between 18 and 80 years of age with HCM who are not participating in a regular exercise regimen (i.e., ≤ 30 minutes of exercise, ≤ 1 day per week for the previous 3 months) and randomize them to a moderate intensity exercise regimen or usual activity. All patients will be administered a pre-screening questionnaire in order to determine eligibility based on baseline physical activity. This will be a collaborative effort with investigators from Stanford University who will secure their own funding. Target enrollment is 64 patients at each of the two centers. This project has already received IRB approval.
Inclusion criteria: 1. Age ≥ 18 years and ≤ 80.
2. Diagnosis of hypertrophic cardiomyopathy, defined by the presence of unexplained leftventricular hypertrophy > 13 mm in any wall segment.
3. Agreement to be a participant in the study protocol and willing/able to return for follow-up.
Exclusion criteria: 1. Opposition to refraining from competitive or organized sports (such as basketball, ice hockey, soccer, and football), burst activity (such as sprinting, racquetball/squash, singles tennis), or heavy isometric exercise (such as body building or bench-pressing) for the duration of the study (1 year). 2. History of exercise-induced syncope or arrhythmias. 3. Medically refractory LV outflow tract obstruction being evaluated for septal reduction therapy. 4. Less than 3 months post septal reduction therapy (surgery or catheter based intervention). 5. Hypotensive response to exercise (> 20 mmHg drop in systolic blood pressure from peak blood pressure to post exercise blood pressure). 6. Pregnancy. 7. Worsening clinical status in the last 3 months, advanced heart failure (NYHA IV) or angina (CCS IV). 8. Left ventricular systolic dysfunction (LVEF<55%). 9. ICD placement in last 3 months or scheduled. 10. Life expectancy less than 12 months. 11. Inability to exercise due to orthopedic or other non-cardiovascular limitations.
At our center, the average peak VO2 for patients with HCM is 24 ml/kg/min, which is in agreement with published measurements from our Stanford collaborators.
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Previous studies in patients with chronic heart failure have demonstrated an approximately 20% increase in peak oxygen consumption with 8 -12 weeks of exercise.
Adherence will be tracked by completion of physical activity logs, telephone follow-ups including the Stanford 7-day recall (7-DR), downloadable data from heart rate monitors and pedometers, and selfreported percentage of time at or exceeding the prescribed training program. The 7-DR has been widely used and validated to assess physical activity levels. It assesses both work and leisure-time activities for the previous seven days. Subjects are asked to recall the number of hours spent sleeping and engaged in moderate [4 metabolic equivalents (METs)], hard (6 METs), and very hard (10.0 METs) physical activity for weekend and week days separately. The time spent performing light activity (2 METs) is determined by subtracting the time included in sleep, moderate, hard, and very hard activity from 24 hours. The physical activity data will be computed as min/d and MET min/d (calculated as the MET intensity times the minutes reported for each type of activity). Energy expenditure will then be computed as follows: MET minutes x (body weight in kilograms/60).
Aim 1: To determine the safety of a moderate intensity exercise training program in patients with HCM.
Participants will be randomized to a moderate intensity home exercise regimen or usual activity. The exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The exercise training protocol will be custom designed in consultation with an exercise physiologist after the initial cardiopulmonary exercise testing data have been gathered, such that patients begin exercising at a low intensity (60% of the heart rate reserve = resting heart rate + 0.6 [peak heart rate -resting heart rate]). A rating of perceived exertion on the Borg scale will be used as a secondary measure to help determine goal exercise intensity. The goal of the first week of the protocol is at least 20 minutes of exercise at 60% of the heart rate reserve during each of 3 days. From that point, the exercise prescription will be designed to first increase duration of exercise by 5-10 minutes every week up to 60 minutes of exercise per day and incrementally increase training intensity to a goal of 80% of the heart rate reserve only during the 1 st month of the study protocol, and then maintain the same program for months 2-4. The modes of exercise will include cycling (stationary or routine), walk-jog protocols, and elliptical training. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
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Participants will be counseled to hydrate adequately during exercise, and to be alert to warning signs that should prompt them to stop exercising and contact the study coordinator. All study participants will keep an exercise log and be provided with heart rate monitors and pedometers. All patients will wear auto-triggered arrhythmia detection monitors for the first month of study initiation and keep a log of any symptoms they experience during exercise. Additionally, all study participants will wear a 24-hour Holter monitor at the end of the study protocol.
Aim 2: To determine whether exercise training improves functional capacity, clinical phenotypic characteristics, and quality of life in patients with HCM.
The following testing will be performed at study initiation and termination (4 months). 1. Cardiopulmonary exercise testing in combination with echocardiography. 2. Cardiac magnetic resonance imaging in patients without implantable devices. 3. Serum biomarkers of stretch activation (i.e., BNP). 4. Minnesota Living with Heart Failure, Quick Inventory of Depressive Symptomatology (Self-Report) and SF36v questionnaires.
Patients will be given new exercise logs at the end of the 4-month protocol period and these logs will be reviewed 2 months later (6 months after study initiation). They will also take the three quality of life questionnaires again at this time. Additionally, they will be asked to complete a survey about the research study itself. Finally, all patients will be asked to repeat a cardiopulmonary exercise test 1 year after study initiation and take the quality of life questionnaires again at that time.
The primary outcome measure will be the change in peak oxygen consumption and anaerobic threshold. Secondary outcomes will include changes in: 
Statistical Analysis
Clinical data will be collected, coded and entered into Velos, an ongoing database generated and managed in conjunction with MICHR. Descriptive statistics will be reported as mean ± SD. All major treatment comparisons between the randomized groups will be performed according to the intentionto-treat principle: that is, patients will be analyzed -and end points will be attributed -according to the treatment arm to which patients are randomized regardless of non-adherence. Comparisons between groups will be performed by unpaired t tests for continuous variables and 2 or Fisher's exact test for categorical variables. Changes in continuous variables over time within each group, and between groups, will be assessed by paired t-tests. The bivariate correlations procedure will be used to compute Pearson's correlation coefficients with the significance levels. For all subjects, multiple linear regression analysis will be performed for change in the peak VO2 at month 4 from baseline as the dependent variable, with baseline demographic and clinical characteristics (age, sex, genetic status, and site) as independent variables. Results will be reported as means with 95% confidence intervals. Two-sided P values will be calculated for all statistical analyses. Significance will be defined as P less than 0.05.
If the analysis of the primary endpoint is not significant, this may reflect noncompliance with the randomization assignment. As we expect that some subjects in the usual activity will initiate an exercise program, and conversely that some subjects in the exercise arm will be non-adherent to their prescribed exercise, we intend to perform a secondary analysis where patients will be divided into quartiles based on total energy expenditure. Linear regression will be used to compare differences in peak VO2 from baseline to month 4 among patients in each quartile of energy expenditure, controlling for the same variables as above (age, sex, race, etc). We will use SAS statistical software for statistical analysis. These statistical methods were prepared under the consultation of MICHR Statistical Core.
Expected Results and Limitations
Our overall expectation is that moderate intensity exercise training will be safe in HCM patients over a broad age range and spectrum of disease severity. We do not anticipate that exercise training at this level will provoke or exacerbate symptoms of heart failure or angina, or promote arrhythmias. We expect that exercise training will be feasible in the majority of study participants and result in a significant increase in functional capacity, as measured by the primary outcome of mean change in peak oxygen consumption. However, there is a possibility that we may identify a subgroup(s) of HCM patients who do not tolerate or respond to advancement of an exercise protocol. There are data from our Stanford collaborators and others that exercise intolerance in HCM patients is related to parameters of diastolic dysfunction 51 . Impaired diastolic filling will limit stroke volume augmentation with exercise, thereby limiting contractile reserve. Additional potential mechanisms of exercise intolerance include provocable LV outflow tract obstruction and abnormal vasomotor or chronotropic responses. What is not known, that our study will address, is whether exercise intolerance related to any of the above mechanisms can be partly overcome by exercise training, or whether certain hemodynamic profiles will be self-limiting and unresponsive to an exercise training regimen.
We fully acknowledge the likelihood that our study will be underpowered to definitively detect any effect (beneficial or harmful) of an exercise intervention on secondary outcomes related to clinical phenotype. The primary reason for this is the insensitivity of clinical imaging and circulating biomarkers to detect early phenotypic changes in a 4 month period in a disease that develops and progresses over a lifetime. We obviously are unable to examine changes in myocardial histology, biochemistry, or signaling as would be done in animal studies. Our intention is then to use data from 8 this pilot study as a springboard to launch a larger, multicenter exercise training study with other HCM centers across the country that will be sufficiently powered to determine effects of exercise training on HCM disease progression and long-term outcomes. Diagnosis of hypertrophic cardiomyopathy, defined by the presence of unexplained left ventricular hypertrophy ≥ 13 mm in any wall segment 3.
Agreement to be a participant in the study protocol and willing/able to return for follow-up B.
Exclusion Criteria 1. Opposition to refraining from competitive or organized sports (such as basketball, ice hockey, soccer, and football), burst activity (such as sprinting, racquetball/squash, singles tennis), or heavy isometric exercise (such as body building or bench pressing) for the duration of the study (1 year).
2.
History of exercise-induced syncope or arrhythmias (VT/VF/NSVT) 3.
Medically refractory LV outflow tract obstruction being evaluated for septal reduction therapy 4.
Less than 3 months post septal reduction therapy (surgery or catheter-based intervention 5.
Hypotensive response to exercise (>20 mmHg drop in systolic blood pressure from peak blood pressure to post exercise blood pressure 6. Pregnancy 7.
Worsening clinical status in the last 3 months, NYHA IV, CCS IV 8.
ICD placement in the last 3 months or scheduled 9.
LV systolic dysfunction or diagnosis of end-stage HCM 10.
Life expectancy < 12 months 11.
Inability to exercise due to orthopedic or other non-cardiovascular limitations
II. Screening
A Record both waist circumference and the ratio 4.
Calculate BMI 5.
Record HR, SBP, DBP 6.
Carotid upstroke: normal, reduced, bifid 7.
Record presence/absence S3, S4 8.
Record presence/absence of outflow murmur (grade 1-6, none); record maneuver response (Valsalva, squat to stand; no change, increase, decrease, not done) 9.
Record presence/absence of MR murmur 10.
Record presence/absence JVD 11.
Record peripheral edema (none, 1-4) 12.
Record lung exam findings: CTAB, decreased BS in bases, wheeze, crackles C. Cardiac MRI -1.5 Tesla magnet (Philips Achieva) MRI at UMHS or EAA
1.
All sequences acquired with cardiac gating.
2.
Breath-hold cine imaging performed using a retrospectively gated segmented balanced steady-state free precession sequence in the short axis plane covering the ventricles from the apex to base, 3 LV long axis planes (horizontal, vertical, and LVOT long axis), and a coronal/oblique plane of the LVOT. Vertical and horizontal line tagging performed using a SPAMM sequence in the short axis plane (one slice each through the base, mid-portion, and apex Goal of the first week of exercise is 3 days per week, at least 20 minutes at 60% HRR during each session 3.
Devise an exercise prescription that will first increase duration of exercise by 5-10 minutes every week up to 60 minutes of exercise per day and incrementally increase training intensity to a goal of 70% of the heart rate reserve during the first month and maintain regimen for months 2-4.
4.
Modes of exercise will include cycling (stationary or routine), walk-jog protocols, and elliptical. 5.
Again, educate participants about the recommended national guidelines for recreational exercise, hydration, and warning symptoms that should prompt them to stop exercising and contact study coordinator (lightheadedness, chest pain, syncope).
6.
Handouts provided to all exercising patients about warning symptoms and hydration.
VII.
Home Obstruction defined as resting left ventricular outflow tract peak pressure gradient ≥ 30 mm Hg. c Genetic testing included the sequencing of at least 9 sarcomere genes (eMethods). Patients were classified as having a pathogenic mutation if at least one disease-causing mutation in one of the 9 genes was identified. Variants were considered of uncertain significance if they could not be definitely classified as either disease-causing or benign. Sarcomere mutation negative patients did not have any variants identified in any of the 9 sarcomere genes. 
